Immunome Management
Management criteria checks 0/4
Immunome's CEO is Clay Siegall, appointed in Jan 2023, has a tenure of 1.25 years. directly owns 0.54% of the company’s shares, worth $4.88M. The average tenure of the management team and the board of directors is 0.5 years and 2.8 years respectively.
Key information
Clay Siegall
Chief executive officer
n/a
Total compensation
CEO salary percentage | n/a |
CEO tenure | 1.3yrs |
CEO ownership | 0.5% |
Management average tenure | less than a year |
Board average tenure | 2.8yrs |
Recent management updates
Recent updates
Immunome: Why It Has Doubled Over The Last Month
Jan 18Will Immunome (NASDAQ:IMNM) Spend Its Cash Wisely?
Mar 17Is Immunome (NASDAQ:IMNM) In A Good Position To Deliver On Growth Plans?
Nov 20Immunome GAAP EPS of -$0.74
Aug 05Here's Why We're Watching Immunome's (NASDAQ:IMNM) Cash Burn Situation
Aug 05Immunome gains 34% after preclinical data on COVID-19 antibody
Jun 30We Think Immunome (NASDAQ:IMNM) Can Afford To Drive Business Growth
Feb 21Companies Like Immunome (NASDAQ:IMNM) Are In A Position To Invest In Growth
Oct 02Immunome launches $27M private placement
Apr 26Do Institutions Own Immunome, Inc. (NASDAQ:IMNM) Shares?
Mar 12Read This Before Selling Immunome, Inc. (NASDAQ:IMNM) Shares
Jan 18Immunome EPS misses by $7.22
Nov 17CEO
Clay Siegall (62 yo)
1.3yrs
Tenure
Dr. Clay B. Siegall, Ph D., serves as Chairman since December 13, 2023 at Tourmaline Bio, Inc. He is Chief Executive Officer & President of MorphImmune, Inc. since March 2023. He co-founded Seagen Inc. (fo...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 1.3yrs | no data | 0.54% $ 4.9m | |
Interim CFO & Executive VP of Operations | less than a year | no data | 0.033% $ 303.4k | |
Principal Accounting Officer | less than a year | no data | 0.020% $ 184.1k | |
Chief Technical Officer | less than a year | no data | no data | |
Chief Scientific Officer | 1.3yrs | no data | no data | |
Chief Legal Officer | 3.5yrs | US$1.64m | 0.0093% $ 84.9k | |
Chief Strategy Officer | 1.3yrs | no data | 0.071% $ 646.3k | |
Chief Medical Officer | less than a year | no data | no data | |
Chief Business Officer | less than a year | no data | no data |
0.5yrs
Average Tenure
48yo
Average Age
Experienced Management: IMNM's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 1.3yrs | no data | 0.54% $ 4.9m | |
Member of Scientific Advisory Board | no data | no data | no data | |
Director | 6.3yrs | US$47.14k | 0.68% $ 6.2m | |
Member of Scientific Advisory Board | no data | no data | no data | |
Lead Independent Director | 1.3yrs | no data | 0.33% $ 3.0m | |
Director | 1.3yrs | no data | no data | |
Member of COVID-19 Advisory Board | 2.8yrs | no data | no data | |
Director | less than a year | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of COVID-19 Advisory Board | 3.6yrs | no data | no data | |
Member of COVID-19 Advisory Board | 3.6yrs | no data | no data | |
Member of COVID-19 Advisory Board | 3.6yrs | no data | no data |
2.8yrs
Average Tenure
59yo
Average Age
Experienced Board: IMNM's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.